Placebo News and Research

RSS

Experimental drug helps patients with advanced colon cancer

According to results from a new clinical trial, an experimental cancer drug regorafenib appears to extend survival slightly in patients with metastatic colorectal cancer. Regorafenib is a so-called multikinase inhibitor, which targets several of the ways cancer develops and grows, researchers said.

19 Jan 2012

New research into treatment, prognosis and early detection of GI cancers

New research into the treatment, prognosis and early detection of gastrointestinal cancers was released today in advance of the ninth annual Gastrointestinal Cancers Symposium being held January 19-21, 2012, at The Moscone West Building in San Francisco, Calif.

19 Jan 2012

Pfizer and Medivation drop further testing of failed Alzheimer’s drug

A phase III clinical trial of an investigational Alzheimer's disease drug dimebon failed to show encouraging results dooming its future according to its commercial sponsors.

18 Jan 2012

Cangrelor allows stent patients to be 'bridged' to cardiac surgery

New findings from a research study led by physicians at Scripps Health reveal that the investigational drug cangrelor has the unique properties of achieving very fast blood thinning effects when needed to protect from heart attacks, but also dissipates rapidly so patients can undergo surgery without the excessive bleeding often associated with blood thinning medications.

18 Jan 2012

Memory retraining using mSMT increases cerebral activation in MS patients

Neuroscientists at Kessler Foundation have documented increased cerebral activation in patients with multiple sclerosis (MS) following memory retraining using the modified Story Memory Technique (mSMT).

18 Jan 2012

Pfizer, Medivation report results from dimebon Phase 3 trial on AD

Medivation, Inc. and Pfizer Inc. today announced results from the CONCERT trial, which is a Phase 3 trial that evaluated dimebon (latrepirdine) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer's disease.

18 Jan 2012

Regorafenib lengthens lives of patients with metastatic colorectal cancer

An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.

17 Jan 2012

Vitamin D provides no relief from chronic obstructive pulmonary disease

Earlier studies have suggested that up to three quarters of people with severe chronic obstructive pulmonary disease, or COPD, are deficient in the vitamin. So it was thought that giving them extra vitamin D might help prevent exacerbations in symptoms or trips to the hospital because of shortness of breath or mucus in the airways. Belgian researchers have refuted this claim.

17 Jan 2012

Angioplasty improves quality of life in MS patients

Although using angioplasty to treat multiple sclerosis (MS) is highly controversial, sufferers often insist it helps - in some cases dramatically, such as allowing them to walk without a cane. Patients with less severe MS also reported additional quality of life improvements, such as being able to talk more clearly, after having treatment to open blocked blood vessels in the chest and neck, according to research being presented at the 24th annual International Symposium on Endovascular Therapy.

17 Jan 2012

ViroPharma's NDS for Cinryze receives Health Canada's Priority Review status

ViroPharma Incorporated today announced that Health Canada has granted the company Priority Review status for its New Drug Submission (NDS) for Cinryze (C1 inhibitor [human]).

13 Jan 2012

Exposure to light appears to have therapeutic effects on Alzheimer's patients

Exposure to light appears to have therapeutic effects on Alzheimer's disease patients, a Wayne State University researcher has found.

12 Jan 2012

USPTO issues patent to Unigene's peptide-based therapeutics for obesity

Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that it had been granted U.S. Patent No. 8,076,291 from the United States Patent and Trademark Office.

11 Jan 2012

Shire, Janssen enter development and marketing agreement for Resolor

Shire plc, the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor (prucalopride) in the United States (US) in an agreement with Janssen Pharmaceutica N.V.

11 Jan 2012

Nicotine patch may help those with mild dementia

The nicotine patch designed to help people quit smoking can also improve memory in older adults with mild cognitive impairment, or MCI, a small clinical trial found.

10 Jan 2012

ADHD diet: Review of studies

A new review finds that some foods may not be good for children with attention deficit-hyperactivity disorder (ADHD). Fast foods, red meat, processed foods, soft drinks, high fat dairy foods and potato chips may not be right.

10 Jan 2012

Shire acquires rights to develop and market Resolor in the U.S.

10 Jan 2012

Nicotine patch may help improve mild memory loss in older adults

Using a nicotine patch may help improve mild memory loss in older adults, according to a study published in the January 10, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

10 Jan 2012

Nicotine patch may boost memory in individuals with MCI

Wearing a nicotine patch may help improve memory loss in older adults with mild cognitive impairment, according to a study published today in Neurology, the medical journal of the American Academy of Neurology.

10 Jan 2012

Combination of GXR and psychostimulant safe and effective for children with ADHD

While pharmacologic agents have a demonstrated efficacy in children with Attention-deficit/hyperactivity disorder (ADHD), some children have suboptimal response to a single pharmacologic agent.

9 Jan 2012

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

Baxter International Inc. today announced that the company has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration (FDA) for approval of GAMMAGARD LIQUID 10% for the treatment of multifocal motor neuropathy.

From Baxter International Inc. 9 Jan 2012